The oncolytic peptide LTX-315 overcomes resistance of cancers to immunotherapy with CTLA4 checkpoint blockade-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The oncolytic peptide LTX-315 overcomes resistance of cancers to immunotherapy with CTLA4 checkpoint blockade

Published:2016-04-15 Issue:6 Volume:23 Page:1004-1015
ISSN:1350-9047
Container-title:Cell Death & Differentiation
language:en
Short-container-title:Cell Death Differ

Author:

Yamazaki T,Pitt J M,Vétizou M,Marabelle A,Flores C,Rekdal Ø,Kroemer G,Zitvogel L

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology,Molecular Biology

Link

http://www.nature.com/articles/cdd201635.pdf

Reference44 articles.

1. Marabelle A, Kohrt H, Caux C, Levy R . Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res 2014; 20: 1747–1756.

2. Church SE, Galon J . Tumor microenvironment and immunotherapy: the whole picture is better than a glimpse. Immunity 2015; 43: 631–633.

3. Fridman WH, Pages F, Sautes-Fridman C, Galon J . The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012; 12: 298–306.

4. Marabelle A, Kohrt H, Sagiv-Barfi I, Ajami B, Axtell RC, Zhou G et al. Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Invest 2013; 123: 2447–2463.

5. Brody JD, Ai WZ, Czerwinski DK, Torchia JA, Levy M, Advani RH et al. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol 2010; 28: 4324–4332.

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antimicrobial peptides: Source, application and recent developments;Process Biochemistry;2024-10

2. Engineering nanomedicines for immunogenic eradication of cancer cells: Recent trends and synergistic approaches;Acta Pharmaceutica Sinica B;2024-06

3. ANTICANCER IMMUNOGENIC POTENTIAL OF ONCOLYTIC PEPTIDES: RECENT ADVANCES AND NEW PROSPECTS;Experimental Oncology;2024-05-31

4. Immunogenic oncolysis by tigilanol tiglate;OncoImmunology;2024-05-27

5. A Transformable Specific‐Responsive Peptide for One‐Step Synergistic Therapy of Bladder Cancer;Small;2024-04-25

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3